Liquidia (LQDA) Q4 2025 earnings review
Explosive Launch Drives Liquidia to First GAAP Profit
Liquidia's commercial launch of YUTREPIA has been nothing short of explosive, propelling the company from a cash-burning clinical stage to GAAP profitability in just two quarters. Total revenue surged to $92.0M in Q4, entirely driven by $90.1M in YUTREPIA net sales. This scale unlocked massive operating leverage: net income reversed from a $38.5M loss a year ago to a $14.6M profit today. While the legacy Treprostinil service revenue is decelerating, the company is now fully funded from operations to advance its next-generation L606 pipeline without immediate dilution risk.
🐂 Bull Case
YUTREPIA sales reached $90.1M in just its second full quarter. With over 3,600 unique prescriptions and 2,900 patients treated since June, the adoption curve is exceptionally steep.
The company reported $14.6M in GAAP net income and $27.3M in Adjusted EBITDA in Q4. This cash generation entirely funds future pipeline expansion.
🐻 Bear Case
SG&A costs soared to $48.2M in Q4 from $21.2M a year ago. While justified by revenue growth, the absolute cost base requires YUTREPIA sales to maintain current altitudes.
Service revenue from the Sandoz promotion agreement dropped 34% YoY to $1.9M. It's now a negligible part of the business but remains a drag on overall growth rates.
⚖️ Verdict: 🟢🟢
Bullish. Flipping from deep clinical-stage losses to a 16% net profit margin within two quarters of a product launch is rare. The volume uptake confirms YUTREPIA as a highly disruptive asset.
Key Themes
YUTREPIA Launch Accelerating
The core growth engine is firing perfectly. Net product sales accelerated from $6.5M in 25Q2 to $51.7M in 25Q3, and now $90.1M in 25Q4. The prescription-to-start conversion rate remains robust at over 85%, and the prescriber base expanded to 860. More than a quarter of these prescribers have referred 5 or more patients, showing deep penetration.
Operating Leverage Reversing Losses
The company achieved a massive break in its financial trend. Adjusted EBITDA reached $27.3M in Q4. The high margin profile of inhaled therapies means that incremental revenue drops straight to the bottom line once commercial infrastructure costs are covered.
PRINT Technology & L606 Innovation
Liquidia's proprietary PRINT technology—which allows precise engineering of inhaled drug particles—is the foundation of YUTREPIA's clinical success. Management is now leveraging this cash flow to advance L606, an investigational liposomal treprostinil formulation designed for twice-daily dosing, into global pivotal trials for PH-ILD.
Service Revenue Decelerating
Contradicting the overall hyper-growth narrative, the legacy service revenue segment is a persistent laggard. Q4 service revenue fell 34% YoY from $2.9M to $1.9M due to lower sales volumes of Treprostinil Injection. While overshadowed by YUTREPIA, it represents a deteriorating legacy cash flow stream.
SG&A Expense Surge
Selling, general, and administrative expenses are accelerating rapidly, reaching $48.2M in Q4 (up 127% YoY). Full-year SG&A nearly doubled to $157.2M. While currently supported by explosive revenue growth, any future flattening of the YUTREPIA adoption curve would quickly pressure margins due to this expanded fixed cost base.
Persistent Litigation Overhang
The company explicitly cited a $5.3M increase in full-year legal fees related to ongoing YUTREPIA litigation. Legal disputes with competitor United Therapeutics remain an active threat that could theoretically disrupt commercialization, despite Liquidia's current market momentum.
Other KPIs
Reversing the historical cash burn. Cash balances increased by $33 million sequentially from Q3 ($157.5M), cleanly reflecting the positive operating cash flow generated by YUTREPIA sales. This balance sheet strength completely removes near-term equity dilution risks.
Stable YoY (Q4 2024 was $16.5M). Full-year R&D actually dropped 18% to $39.3M, reflecting a strategic shift of personnel and resources away from early research toward YUTREPIA commercialization and specific pivotal trial execution for L606.
Guidance
Stable/Accelerating expectation. Management did not provide specific revenue or EPS ranges for 2026. However, they signaled an expectation for accelerating adoption, stating plans to 'deepen prescriber adoption, grow our sales force, expand YUTREPIA's clinical evidence... all of which will be funded from operations.'
Key Questions
Gross-to-Net Dynamics
With YUTREPIA achieving $90M in net sales in its second full quarter, what is the steady-state gross-to-net discount now that major commercial payer contracts are fully integrated?
L606 Clinical Timeline
Given the pivot to funding L606 from current operations, what is the precise timeline for initiating and completing the global pivotal placebo-controlled efficacy study for PH-ILD?
Litigation Update
Can you provide an updated view on the timeline for a definitive legal resolution regarding the ongoing patent litigation with United Therapeutics?